A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Latest Information Update: 31 Dec 2024
Price :
$35 *
At a glance
- Drugs Trametinib (Primary)
- Indications Gastrointestinal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 21 Dec 2024 Planned End Date changed from 18 Dec 2025 to 20 Dec 2025.
- 21 Dec 2024 Planned End Date changed from 18 Dec 2025 to 20 Dec 2025.
- 20 Dec 2024 Planned End Date changed from 1 Nov 2025 to 18 Dec 2025.